{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:02:25Z","timestamp":1787738545466,"version":"build-2784847793"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.14283\/jpad.2022.29","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T08:40:22Z","timestamp":1646728822000},"page":"231-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report"],"prefix":"10.1016","volume":"9","author":[{"given":"Serge","family":"Gauthier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Knopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Doody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Iwatsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.14283\/jpad.2022.29_bib1","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/acn3.51457","article-title":"Amyloid-dependent and amyloid-independent effects of tau in individuals without dementia","volume":"8","author":"Therriault","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"10.14283\/jpad.2022.29_bib2","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","article-title":"Microglial activation and tau propagate jointly across Braak stages","volume":"27","author":"Pascoal","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.14283\/jpad.2022.29_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer Dement"},{"issue":"1","key":"10.14283\/jpad.2022.29_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ana.25246","article-title":"Combined neuropathological pathways account for age-related risk of dementia","volume":"84","author":"Power","year":"2018","journal-title":"Ann Neurol"},{"issue":"4","key":"10.14283\/jpad.2022.29_bib5","first-page":"S63","article-title":"Baseline EMBARK data from EMERGE, ENGAGE and PRIME participants in the EMBARK re-dosing study","volume":"8","author":"Cohen","year":"2021","journal-title":"JPAD"},{"key":"10.14283\/jpad.2022.29_bib6","unstructured":"Hansson O, Nisenbaum L, Chen T, Rajagovindan R, Tian Y, Muralidharan KK et al. Dose- and time- dependant changes in plasma p-tau181 in patients treated with aducanumab in the ENGAGE and EMERGE trials. Presented at the 14th CTAD Conference, Boston, Late Braking News Round Table 8."},{"key":"10.14283\/jpad.2022.29_bib7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nature Medicine"},{"issue":"18","key":"10.14283\/jpad.2022.29_bib8","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2022.29_bib9","first-page":"13","article-title":"\u2018The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography'","author":"Sanchez","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.14283\/jpad.2022.29_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/nan.12213","article-title":"Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging","volume":"41","author":"Ghetti","year":"2015","journal-title":"Neuropathology and applied neurobiology"},{"key":"10.14283\/jpad.2022.29_bib11","first-page":"371","article-title":"\u2018Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies'","author":"Chang","year":"2021","journal-title":"Science"},{"key":"10.14283\/jpad.2022.29_bib12","doi-asserted-by":"crossref","first-page":"134919","DOI":"10.1016\/j.neulet.2020.134919","article-title":"Targeting tau: Clinical trials and novel therapeutic approaches","volume":"731","author":"VandeVrede","year":"2020","journal-title":"Neurosci Lett"},{"key":"10.14283\/jpad.2022.29_bib13","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.cell.2020.10.029","article-title":"Tau PTM profiles indentify patient heterogeneity and stages of Alzheimer's disease","volume":"183","author":"Wesseling","year":"2020","journal-title":"Cell"},{"key":"10.14283\/jpad.2022.29_bib14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","article-title":"Structure-based classification of tauopathies","volume":"598","author":"Shi","year":"2021","journal-title":"Nature"},{"key":"10.14283\/jpad.2022.29_bib15","author":"Horie"},{"issue":"1","key":"10.14283\/jpad.2022.29_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s40478-020-01019-z","article-title":"Regional Correlation of Biochemical Measures of Amyloid and Tau Phosphorylation in the Brain","volume":"8","author":"Horie","year":"2020","journal-title":"Acta Neuropathologica Communications"},{"key":"10.14283\/jpad.2022.29_bib17","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","article-title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","volume":"27","author":"Dam","year":"2021","journal-title":"Nat Med"},{"key":"10.14283\/jpad.2022.29_bib18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","article-title":"\u2018Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial'","volume":"20","author":"Hoglinger","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.14283\/jpad.2022.29_bib19","first-page":"13","article-title":"\u2018Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease'","author":"Ayalon","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.14283\/jpad.2022.29_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo- controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.14283\/jpad.2022.29_bib21","doi-asserted-by":"crossref","first-page":"105120","DOI":"10.1016\/j.nbd.2020.105120","article-title":"Characterization of tau binding by gosuranemab","volume":"146","author":"Sopko","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.14283\/jpad.2022.29_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.neurobiolaging.2014.09.007","article-title":"Human secreted tau increases amyloid-beta production","volume":"36","author":"Bright","year":"2015","journal-title":"Neurobiology of aging"},{"key":"10.14283\/jpad.2022.29_bib23","doi-asserted-by":"crossref","first-page":"109855","DOI":"10.1016\/j.celrep.2021.109855","article-title":"Tau reduction affects excitatory and inhibitory neurons differently, reduces excitation\/inhibition ratios, and counteracts network hypersynchrony","volume":"37","author":"Chang","year":"2021","journal-title":"Cell Rep"},{"key":"10.14283\/jpad.2022.29_bib24","unstructured":"Monteiro C. Presented at the 14th Conference Clinical Trials Alzheimer's Disease, November 9\u201312, 2021, Boston."},{"key":"10.14283\/jpad.2022.29_bib25","doi-asserted-by":"crossref","unstructured":"Mummery, C., C Junge, H Kordasiweicz, L. Mignong, K. Moore, C. Yun, T. Baumann, D. Li, D.A. Norris, R. Crean, D. Graham, E. Huang, E. Ratti, and R.M. Lane. 2021. \u201cResults of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase 1bStudy of Lumbar Intrathecal Bolus Administrations of Antisense Oligonucleotide (ISIS 814907; BIIB080) Targeting Tau mRNA in Patients with Mild Alzheimer's Disease.\u201d In Alzheimer's Association International Conference. Denver.","DOI":"10.1002\/alz.051871"},{"key":"10.14283\/jpad.2022.29_bib26","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/13543776.2021.1947242","article-title":"O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature","volume":"31","author":"Bartolome-Nebreda","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.14283\/jpad.2022.29_bib27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1523\/JNEUROSCI.2336-15.2016","article-title":"Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration","volume":"36","author":"Gentry","year":"2016","journal-title":"J Neurosci"},{"key":"10.14283\/jpad.2022.29_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neurobiolaging.2019.12.009","article-title":"Rho-kinase ROCK inhibitors reduce oligomeric tau protein","volume":"89","author":"Hamano","year":"2020","journal-title":"Neurobiol Aging"},{"key":"10.14283\/jpad.2022.29_bib29","doi-asserted-by":"crossref","first-page":"595532","DOI":"10.3389\/fneur.2020.595532","article-title":"Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation","volume":"11","author":"Alquezar","year":"2020","journal-title":"Front Neurol"},{"key":"10.14283\/jpad.2022.29_bib30","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.14283\/jpad.2022.29_bib31","first-page":"11","article-title":"Shin","author":"Hyun","year":"2021","journal-title":"\u2018Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases', Life (Basel)"},{"key":"10.14283\/jpad.2022.29_bib32","first-page":"11","article-title":"2019. \u2018A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy'","author":"Hernandez","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.14283\/jpad.2022.29_bib33","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat Aging"},{"key":"10.14283\/jpad.2022.29_bib34","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1038\/s41598-019-41105-4","article-title":"Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcgamma-receptor binding and functional lysosomes","volume":"9","author":"Andersson","year":"2019","journal-title":"Sci Rep"},{"key":"10.14283\/jpad.2022.29_bib35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","article-title":"Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease","volume":"8","author":"Roberts","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.14283\/jpad.2022.29_bib36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.14283\/jpad.2022.29_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU Next Generation Alzheimer's Prevention Trial: Adaptive Design and Disease Progression Model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimer's & Dementia: The Journal of the Alzheimer's Association"},{"key":"10.14283\/jpad.2022.29_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nature Reviews. Disease primers"},{"key":"10.14283\/jpad.2022.29_bib40","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s13311-017-0541-z","article-title":"Targeting neural hyperactivity as a treatment to stem progression of late-onset Alzheimer's disease","volume":"14","author":"Haberman","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.14283\/jpad.2022.29_bib41","series-title":"Disease-specific interactome alterations via epichaperomics: the case for Alzheimer's disease","author":"Ginsberg","year":"2021"},{"key":"10.14283\/jpad.2022.29_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb1717","article-title":"Endosomal recycling reconciles the Alzheimer's disease paradox","volume":"12","author":"Small","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.14283\/jpad.2022.29_bib43","doi-asserted-by":"crossref","first-page":"108420","DOI":"10.1016\/j.celrep.2020.108420","article-title":"Endosomal dysfunction induced by directly overactivating Rab5 recapitulates prodromal and neurodegenerative features of Alzheimer's disease","volume":"33","author":"Pensalfini","year":"2020","journal-title":"Cell Rep"},{"key":"10.14283\/jpad.2022.29_bib44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12974-019-1493-5","article-title":"Deletion of p38\u03b1 MAPK in microgla blunts trauma-induced inflammatory responses in mice","volume":"16","author":"Morganti","year":"2020","journal-title":"Journal of Neuroinflammation"},{"key":"10.14283\/jpad.2022.29_bib45","doi-asserted-by":"crossref","first-page":"e12158","DOI":"10.1002\/trc2.12158","article-title":"Safety and efficacy of sargramostin (GM-CSF) in the treatment of Alzheimer's disease","volume":"7","author":"Potter","year":"2021","journal-title":"Alzheimer's & Dementia"},{"key":"10.14283\/jpad.2022.29_bib46","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1172\/JCI95145","article-title":"Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives","volume":"128","author":"Baker","year":"2018","journal-title":"J Clin Invest"},{"key":"10.14283\/jpad.2022.29_bib47","article-title":"Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial","author":"Gonzales","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2022.29_bib48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.14283\/jpad.2019.49","article-title":"Geroscience and the Role of Aging in the Etiology and Management of Alzheimer's Disease","volume":"7","author":"Sierra","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2022.29_bib49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.14283\/jpad.2019.50","article-title":"Revisiting the Hallmarks of Aging to Identify Markers of Biological Age","volume":"7","author":"Guerville","year":"2020","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2022.29_bib50","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43587-021-00082-y","article-title":"An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging","volume":"1","author":"Sayed","year":"2021","journal-title":"Nat Aging"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724003352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724003352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:11:58Z","timestamp":1737339118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724003352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2274580724003352"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2022.29","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2022.29","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}